<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490942</url>
  </required_header>
  <id_info>
    <org_study_id>XSGO-AF01</org_study_id>
    <nct_id>NCT03490942</nct_id>
  </id_info>
  <brief_title>Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses</brief_title>
  <official_title>Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrated Medical Development</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the&#xD;
      primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion&#xD;
      (CSGI) or placebo. After a 1-week qualification on continuous glucose monitoring (CGM),&#xD;
      subjects will have their baseline hypoglycemia counter-regulatory response hormones&#xD;
      quantified using a step-wise hypoglycemia induction procedure. Subjects meeting eligibility&#xD;
      requirements will be randomized to 1 of 4 treatment groups, 2 glucagon, 2 placebo. Subjects&#xD;
      will receive blinded study drug for 4 weeks, and they will be followed for an additional 26&#xD;
      weeks post-treatment. Subjects' counter-regulatory hormone response will be measured at&#xD;
      baseline, the end of treatment (4 weeks), and 13 and 26 weeks after treatment ends.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary endpoint was not met&#xD;
  </why_stopped>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks treatment with CSGI or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Epinephrine</measure>
    <time_frame>0-30 minutes</time_frame>
    <description>Plasma epinephrine concentration after 30 minutes of induced hypoglycemia. Change from baseline to the end of treatment will be assessed.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hypoglycemia Unawareness</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>CSGI high infusion rate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon given as a continuous subcutaneous infusion for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSGI low infusion rate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon given as a continuous subcutaneous infusion for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo high infusion rate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given as a continuous subcutaneous infusion for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo low infusion rate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given as a continuous subcutaneous infusion for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
    <arm_group_label>CSGI high infusion rate</arm_group_label>
    <arm_group_label>CSGI low infusion rate</arm_group_label>
    <other_name>CSI-Glucagon</other_name>
    <other_name>CGSI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo solution is a non-active formulation containing excipients only.</description>
    <arm_group_label>Placebo high infusion rate</arm_group_label>
    <arm_group_label>Placebo low infusion rate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females diagnosed with type 1 diabetes mellitus for at least 24 months.&#xD;
&#xD;
          2. Random serum C-peptide concentration &lt; 0.5 ng/ml at Screening.&#xD;
&#xD;
          3. Current use of multiple daily dosing insulin treatment &lt; 1 U/(kg*day) total daily dose&#xD;
             either administered with subcutaneous injections or continuous subcutaneous insulin&#xD;
             infusion (CSII).&#xD;
&#xD;
          4. Recurrent severe hypoglycemia as defined by minimally two events during the last year&#xD;
             and at least one the last six months requiring not merely receiving third party&#xD;
             intervention and either confirmation with a measured glucose &lt; 50 mg/dl, or prompt&#xD;
             recovery from impaired consciousness. Events must be documented in patient chart prior&#xD;
             to study entry. Events induced as a part of clinical diagnostics or experimentation do&#xD;
             not qualify.&#xD;
&#xD;
          5. Performs monitoring of glucose minimally 3 times a day. Patients using continuous&#xD;
             glucose monitoring for monitoring should continue to do so during the course of the&#xD;
             study.&#xD;
&#xD;
          6. Age 21-64 years, inclusive, at screening.&#xD;
&#xD;
          7. Willingness to provide informed consent and follow all study procedures, including&#xD;
             using the Medtronic smart phone application &quot;iPRO2mylog&quot; for diabetes data logging and&#xD;
             attending all scheduled visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects using CSII, who do not use a Medtronic pump.&#xD;
&#xD;
          2. Hemoglobin A1c â‰¥9.0% at Screening.&#xD;
&#xD;
          3. Chronic kidney disease stage 4 or 5.&#xD;
&#xD;
          4. Hepatic disease, including serum alanine transaminase (ALT) or aspartate transaminase&#xD;
             (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic&#xD;
             insufficiency as defined as serum albumin &lt; 3.0 g/dL; or serum bilirubin &gt; 2.0.&#xD;
&#xD;
          5. Hematocrit of less than or equal to 30% at Screening.&#xD;
&#xD;
          6. Blood pressure (BP) reading at Screening where systolic BP &lt;90 or &gt;150 mm Hg, or&#xD;
             diastolic BP &lt;50 or &gt;100 mm Hg.&#xD;
&#xD;
          7. Clinically significant echocardiogram (ECG) abnormalities at Screening.&#xD;
&#xD;
          8. Congestive heart failure, New York Heart Association (NYHA) class II, III or IV,&#xD;
&#xD;
          9. History of myocardial infarction, unstable angina or revascularization within the past&#xD;
             6 months.&#xD;
&#xD;
         10. History of a cerebrovascular accident.&#xD;
&#xD;
         11. Current seizure disorder.&#xD;
&#xD;
         12. History of pheochromocytoma or disorder with increased risk of pheochromocytoma&#xD;
             (multiple endocrine neoplasia type 2, neurofibromatosis, or Von Hippel-Lindau&#xD;
             disease).&#xD;
&#xD;
         13. History of insulinoma.&#xD;
&#xD;
         14. Active malignancy within 5 years from Screening, except basal cell or squamous cell&#xD;
             skin cancers. History of breast cancer or malignant melanoma will be exclusionary.&#xD;
&#xD;
         15. Major surgical operation within 30 days prior to Screening.&#xD;
&#xD;
         16. Current bleeding disorder, treatment with warfarin, or platelet count below 50,000 at&#xD;
             Screening.&#xD;
&#xD;
         17. History of allergies to glucagon or glucagon-like products, or any history of&#xD;
             significant hypersensitivity to glucagon or any related products or to any of the&#xD;
             excipients in the investigational formulation.&#xD;
&#xD;
         18. History of glycogen storage disease.&#xD;
&#xD;
         19. Any concurrent illness, other than diabetes, that is not controlled by a stable&#xD;
             therapeutic regimen.&#xD;
&#xD;
         20. Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations&#xD;
             of plasma, packed red blood cells, platelets or quantities less than 500 mL are&#xD;
             allowed at investigator discretion.&#xD;
&#xD;
         21. Active substance or alcohol abuse (more than 21 drinks/wk. for males or 14 drinks/wk.&#xD;
             for females). Subjects reporting active marijuana use and/or testing positive for&#xD;
             tetrahydrocannabinol via rapid urine test will be allowed to participate in the study&#xD;
             at the discretion of the investigator. Subjects positive for other drugs of abuse via&#xD;
             rapid urine test who report use of a prescription or over-the-counter medication that&#xD;
             would explain such a finding will be allowed to participate at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
         22. Administration of glucagon within 14 days of Screening.&#xD;
&#xD;
         23. Pregnant and/or Lactating. For subjects of childbearing potential, there is a&#xD;
             requirement for a negative urine pregnancy test and for agreement to use contraception&#xD;
             and to refrain from breast feeding during the study and for at least 1 month after&#xD;
             participating in the study. Acceptable contraception includes birth control pill /&#xD;
             patch / vaginal ring, Depo-Provera, Norplant, an intra-uterine device, the double&#xD;
             barrier method (the female uses a diaphragm and spermicide and the male uses a&#xD;
             condom), or abstinence.&#xD;
&#xD;
         24. Inadequate venous access.&#xD;
&#xD;
         25. Participation in other studies involving administration of an investigational drug or&#xD;
             interventional device within 30 days or 5 half-lives, whichever is longer, before&#xD;
             Screening for the current study and during the four weeks of study product&#xD;
             administration in the current study.&#xD;
&#xD;
         26. Any reason the principal investigator deems exclusionary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University - Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 25, 2018</study_first_submitted>
  <study_first_submitted_qc>April 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <results_first_submitted>November 4, 2020</results_first_submitted>
  <results_first_submitted_qc>February 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2021</results_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon</keyword>
  <keyword>hypoglycemia counter-regulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03490942/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03490942/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CSGI High Infusion Rate</title>
          <description>Glucagon given as a continuous subcutaneous infusion for 28 days&#xD;
Glucagon: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
        </group>
        <group group_id="P2">
          <title>CSGI Low Infusion Rate</title>
          <description>Glucagon given as a continuous subcutaneous infusion for 28 days&#xD;
Glucagon: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
        </group>
        <group group_id="P3">
          <title>Placebo High Infusion Rate</title>
          <description>Placebo given as a continuous subcutaneous infusion for 28 days&#xD;
Placebo: The placebo solution is a non-active formulation containing excipients only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CSGI High Infusion Rate</title>
          <description>Glucagon given as a continuous subcutaneous infusion for 28 days&#xD;
Glucagon: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
        </group>
        <group group_id="B2">
          <title>CSGI Low Infusion Rate</title>
          <description>Glucagon given as a continuous subcutaneous infusion for 28 days&#xD;
Glucagon: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
        </group>
        <group group_id="B3">
          <title>Placebo High Infusion Rate</title>
          <description>Placebo given as a continuous subcutaneous infusion for 28 days&#xD;
Placebo: The placebo solution is a non-active formulation containing excipients only.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="27" upper_limit="61"/>
                    <measurement group_id="B2" value="37" lower_limit="22" upper_limit="60"/>
                    <measurement group_id="B3" value="39" lower_limit="21" upper_limit="61"/>
                    <measurement group_id="B4" value="41.5" lower_limit="21" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Epinephrine</title>
        <description>Plasma epinephrine concentration after 30 minutes of induced hypoglycemia. Change from baseline to the end of treatment will be assessed.</description>
        <time_frame>0-30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CSGI High Infusion Rate</title>
            <description>Glucagon given as a continuous subcutaneous infusion for 28 days&#xD;
Glucagon: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
          </group>
          <group group_id="O2">
            <title>CSGI Low Infusion Rate</title>
            <description>Glucagon given as a continuous subcutaneous infusion for 28 days&#xD;
Glucagon: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
          </group>
          <group group_id="O3">
            <title>Placebo High Infusion Rate</title>
            <description>Placebo given as a continuous subcutaneous infusion for 28 days&#xD;
Placebo: The placebo solution is a non-active formulation containing excipients only.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Epinephrine</title>
          <description>Plasma epinephrine concentration after 30 minutes of induced hypoglycemia. Change from baseline to the end of treatment will be assessed.</description>
          <units>Pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="150.10"/>
                    <measurement group_id="O2" value="144.4" spread="168.56"/>
                    <measurement group_id="O3" value="167.3" spread="138.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CSGI High Infusion Rate</title>
          <description>Glucagon given as a continuous subcutaneous infusion for 28 days&#xD;
Glucagon: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
        </group>
        <group group_id="E2">
          <title>CSGI Low Infusion Rate</title>
          <description>Glucagon given as a continuous subcutaneous infusion for 28 days&#xD;
Glucagon: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.</description>
        </group>
        <group group_id="E3">
          <title>Placebo High Infusion Rate</title>
          <description>Placebo given as a continuous subcutaneous infusion for 28 days&#xD;
Placebo: The placebo solution is a non-active formulation containing excipients only.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, Version 22</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric emptying</sub_title>
                <description>SAE of impaired gastric emptying on Study Day 100. This subject had a medical history of gastroparesis. The SAE was moderate in intensity, did not result in study discontinuation, was considered not related to study drug by the Investigator</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <description>Subject 03-04, a 31-year-old male in the high rate CSGI group, had a treatment-emergent SAE of foot fracture on Study Day 102, as a result of an accident with a chainsaw.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, Version 22</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Redness of the skin</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>B J. Witkin</name_or_title>
      <organization>Xeris Pharmaceuticals</organization>
      <phone>919-412-6483</phone>
      <email>bwitkin@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

